- Category: HCV Treatment
- Published on Friday, 13 April 2012 00:00
- Written by Liz Highleyman
The U.S. Department of Veterans Affairs (VA) and the Treatment Action Group (TAG) have produced new fact sheets with information about the new hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek).
Both protease inhibitors are approved for use in combination with pegylated interferon (Pegasys or PegIntron) and ribavirin. The triple combination regimen is complex, as boceprevir and telaprevir are taken 3 times daily with food and interferon must be injected.
The VA handouts, available for download at http://www.hepatitis.va.gov/products/patient/triple-therapy-handouts.asp, provide a visual guide with a personal medication schedule and information about what to do if a dose is missed.
The TAG fact sheets, available at http://www.treatmentactiongroup.org/HCV/factsheets, describe how each drug should be used, treatment success rates, common side effects, drug-drug interactions, and information about payment assistance.
Department of Veterans Affairs. Taking Your Hepatitis C Triple Therapy. February 2012.
Treatment Action Group. HCV Factsheets.